REGULATORY GUIDES

Market-entry requirements, made decision-ready.

Jurisdiction-specific guidance on classification, registration, labeling, UDI, evidence packs and compliance boundaries.

VEMERIX regulatory guide cover on a missing EUDAMED device record in October 2026: the 12-month continued-placement window and the separate 18-month certificate upload.
Is a Missing EUDAMED Device Record Still Allowed?If the first EU unit of a UDI-DI was placed before 28 May 2026, Regulation (EU) 2024/1860 gives the manufacturer 12 months from the functionality notice to enter the device record. The Commission graphic prints 28 November 2026. A first unit placed on or after 28 May 2026 needs the record first.October 3, 2026 · 22 min read
ANVISA Brazil medical device market placement and regulatory compliance roadmap under RDC 751/2022, RDC 848/2024, detentor responsibilities, Solicita subject code 80326, 4-year MDSAP CBPF validity, and IN 290/2024 reliance
Placing a Single-Use Medical Device in Brazil: The 2026 ANVISA RouteAn operational regulatory guide for international medical device distributors, OEM buyers, and foreign manufacturers placing sterile single-use devices on the Brazilian market under RDC 751/2022, RDC 848/2024, the 14 August 2026 Código Único transition, 4-year MDSAP CBPF validity, IN 290/2024 AREE reliance, and the 2026 SIUD UDI database.September 27, 2026 · 20 min read
China Class II UDI production clock decision tree comparing Announcement 21 remaining Class II, 2023 No. 22 third-batch 103 varieties, and Announcement 15 exemptions
Does This China Class II Shipment Need a UDI YetAn incoming-inspection and regulatory-clock guide for international distributors, OEM/private-label buyers, and hospital procurement leads evaluating Chinese Class II sterile device shipments, Announcement 21 remaining-variety deadlines, the 103 third-batch catalogue, and Announcement 15 exemptions on 18 September 2026.September 18, 2026 · 16 min read
COFEPRIS Mexico medical device market placement and regulatory compliance roadmap under Ley General de Salud Articles 262 and 376, RIS Article 83 risk classes, 2010/2012 equivalence, and 18 July 2025 Option F lineamientos
How to Place a Medical Device on the Mexican Market in 2026: Registro Sanitario versus 2010 FDA/Canada and 2012 Japan Equivalence Agreements versus Option F Abbreviated Pathway under the 18 July 2025 Lineamientos, IMDRF Management Committee versus MDSAP for GMP Certificates Only, Homoclave COFEPRIS-04-050 Still Physical, the 20 August 2026 Visor, Official LFD Article 195-A Fees, and Why CE / 510(k) / NMPA / MDSAP Do Not Replace a Mexican Sanitary RegistrationAn operational regulatory guide for international medical device distributors, OEM buyers, and foreign manufacturers placing sterile single-use devices on the Mexican market under Ley General de Salud Articles 262 and 376, RIS Article 83 risk classes, the 2010 FDA/Canada and 2012 Japan equivalence agreements, and the 18 July 2025 Option F abbreviated pathway.September 7, 2026 · 22 min read
Japan PMDA medical device market placement and regulatory compliance roadmap under PMD Act Articles 23-2 and 23-2-17, FMR Article 23-2-4, and MHLW Ordinance 169
How to Place a Medical Device on the Japanese Market in 2026: Marketing Authorization Holder versus Designated MAH under PMD Act Articles 23-2 and 23-2-17, Foreign Manufacturer Registration under Article 23-2-4 versus Drug Accreditation, Todokede versus Ninsho versus Shonin, Ordinance 169 and MDSAP, Official Yen Fees, and Why CE / 510(k) / NMPA / HSA Do Not Replace a Japanese LicenceAn operational regulatory guide for international medical device distributors, OEM buyers, and foreign manufacturers placing sterile single-use devices on the Japanese market under PMD Act Articles 23-2, 23-2-4, and 23-2-17, MHLW Ordinance 169, and official PMDA user-fee schedules.September 5, 2026 · 15 min read
South Korea MFDS medical device market placement and regulatory compliance roadmap under Medical Devices Act and Act No. 21263
How to Place a Medical Device on the Korean Market in 2026: Import Business Permission versus Item Notification, Certification or Approval, KGMP and QMS Conformity Recognition after Act No. 21263, Official Fees under Enforcement Rule Article 65, and Why CE / 510(k) / NMPA / HSA Do Not Replace an MFDS LicenceAn operational regulatory guide for international medical device distributors, OEM buyers and manufacturers placing sterile single-use devices on the Republic of Korea market under the Medical Devices Act, Enforcement Rule Article 65 fees, and Act No. 21263 QMS conformity rules.September 3, 2026 · 14 min read
Infographic diagram of Singapore Health Sciences Authority (HSA) medical device market placement framework: SMDR product registration, Class A notification, Singapore Registrant mandate, dealer licences, GN-15 R13 evaluation routes, and 2026 official fees.
How to Place a Medical Device on the Singapore Market in 2026: SMDR versus Class A Notification versus Dealer Licence versus Registrant, GN-15 R13 Evaluation Routes and Malaysia MDA Reliance, Official Fees as of 26 March 2026, and Why CE / 510(k) / NMPA Do Not Replace an HSA ListingA definitive, decision-led guide for international manufacturers and Singapore distributors: navigating Singapore Health Sciences Authority (HSA) medical device registration, SMDR listings, Class A SHARE notifications, Registrant mandates, dealer licences, GN-15 R13 evaluation pathways, and 2026 fee cards.September 1, 2026 · 14 min read
VEMERIX regulatory guide cover illustrating the 2026 Health Canada medical device market placement framework: Medical Device Licence (MDL) for Class II–IV under SOR/98-282 s 26, Medical Device Establishment Licence (MDEL) under GUI-0016, MDSAP QMS filing condition, Schedule 1 risk classification, April 2026 fees including private-label MDL (CAD 179), MDALL verification limits, and SOR/2026-110 Phase 2 coming-into-force rules.
How to Place a Medical Device on the Canadian Market in 2026: Medical Device Licence versus Medical Device Establishment Licence versus Class I, MDSAP as a Licence Condition not a Substitute, Official Fees as of 1 April 2026, and Why SOR/2026-110's Coming-into-Force Date Is Counted from Registration not from the MDCP BulletinAn operational decision guide for international medical-device distributors, private-label/OEM buyers, and overseas manufacturers: navigating Health Canada Medical Device Licences (MDL) under SOR/98-282 s 26, Medical Device Establishment Licences (MDEL) under GUI-0016 Table 1, the mandatory MDSAP quality filing condition, Schedule 1 risk classification, official 1 April 2026 fees including the private-label MDL, MDALL versus MDEL listing verification boundaries, and the SOR/2026-110 modernization coming-into-force timeline.August 30, 2026 · 22 min read
VEMERIX regulatory guide cover illustrating the 2026 Australian medical device market placement workflow: TGA ARTG inclusion under the Therapeutic Goods Act 1989, Australian Sponsor requirements, Manufacturer Evidence pre-approval, TGA classification (Classes I–III), Comparable Overseas Regulator (COR) pathways, and class-phased AusUDID requirements.
How to Place a Medical Device on the Australian Market in 2026: ARTG Inclusion versus Australian Sponsor versus Manufacturer Evidence, TGA Classification, Comparable Overseas Regulator Evidence, and Why 1 July 2026 UDI Starts Only After You Know the TGA ClassAn operational decision guide for international distributors, private-label/OEM buyers, and overseas manufacturers: navigating Australian Register of Therapeutic Goods (ARTG) inclusion under the Therapeutic Goods Act 1989, the Australian sponsor mandate, Manufacturer Evidence pre-approval, TGA risk classification (Classes I, IIa, IIb, III), Comparable Overseas Regulator (COR) pathways, July 2026 fee schedules, and the class-phased 1 July 2026 Unique Device Identification (AusUDID) rollout.August 29, 2026 · 20 min read
VEMERIX regulatory guide cover showing the Saudi Arabia medical device market placement workflow: SFDA MDMA under Law M/54, MDS-G008 risk classification (Classes A–D), May 2025 fee schedule, MDS-G028 bundling rules (3 May 2026), Authorized Representative mandate via GHAD, and MDS-REQ 5 shipment clearance.
How to Place a Medical Device on the Saudi Market in 2026: MDMA versus Authorized Representative versus Establishment License, SFDA Classes A–D, 2025 Fees, and the May 2026 Bundling RulesAn operational decision guide for international distributors, private-label/OEM buyers, and overseas manufacturers: navigating the Kingdom of Saudi Arabia's MDMA requirements under Law M/54, the Technical File Assessment route, SFDA Classes A–D (MDS-G008), the May 2025 fee schedule, the 3 May 2026 bundling criteria (MDS-G028), Authorized Representative mandates, importer establishment licensing, and port-clearance verification.August 25, 2026 · 18 min read